SA53

About Lamassu Biotech

Lamassu Biotech is a private, clinical-stage biotech advancing a pipeline of novel small molecule therapeutics with an emphasis on accelerated development timelines. Its lead programs include SA53, a first-in-class oncology candidate targeting p53 wild-type tumors in Phase I/II, and RABI-767 for acute pancreatitis, which has progressed to Phase II. The company's strategy centers on a collaborative, translational research model that bridges academia and industry to de-risk and expedite the path from discovery to definitive clinical testing.

Therapeutic Areas